Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.49 |
| ▸ | HPGD | P15428 | 10/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | GAA | P10253 | 7/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | GLA | P06280 | 4/20 | 0.44 |
| ▸ | CASP1 | P29466 | 4/20 | 0.44 |
| ▸ | CASP7 | P55210 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29412616 | 1.00 | ALDH1A1 (0.49) | ALDH1A1HPGDKDM4EGAAHSD17B10 | |
| SCHEMBL654011 | 0.86 | MAOB (0.50) | ALDH1A1HPGDKDM4EGAAHSD17B10 | |
| SCHEMBL988406 | 0.82 | NOTUM (0.51) | ALDH1A1HPGDKDM4EGAAHSD17B10 | |
| SCHEMBL17963690 | 0.80 | MAOB (0.34) | ALDH1A1HPGDKDM4EGAAHSD17B10 | |
| SCHEMBL3044086 | 0.78 | HRH1 (0.52) | ALDH1A1HPGDKDM4EGAAHSD17B10 | |
| SCHEMBL1803384 | 0.78 | ALDH1A1 (0.40) | ALDH1A1HPGDKDM4EGAAHSD17B10 | |
| SCHEMBL18723782 | 0.77 | NOTUM (0.41) | ALDH1A1HPGDKDM4EGAAHSD17B10 | |
| SCHEMBL1803386 | 0.77 | HTR2B (0.48) | ALDH1A1HPGDKDM4EGAAHSD17B10 | |
| SCHEMBL3030828 | 0.77 | SETD7 (0.56) | ALDH1A1KDM4EHSD17B10MAPK1KMT2A | |
| SCHEMBL8936327 | 0.77 | HTR2B (0.48) | ALDH1A1HPGDKDM4EGAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12318485-B2 | Methods and compositions for targeted delivery by polymersomes | ROCK BIOMEDICAL, INC. (TW) | 2025-06-03 | — | — | US | claimed |
| US-20230172869-A1 | A NANO-ENABLED VACCINATION APPROACH FOR CORONAVIRUS DISEASE (COVID-19) AND OTHER VIRAL DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-08 | — | — | US | claimed |
| US-11603364-B2 | Acyl hydrazone derivative compounds for treating disease | Alterity Therapeutics Limited (AU) | 2023-03-14 | — | — | US | claimed |
| EP-4138856-A1 | A NANO-ENABLED VACCINATION APPROACH FOR CORONAVIRUS DISEASE (COVID-19) AND OTHER VIRAL DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-01 | — | — | EP | claimed |
| US-20220064142-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | ADJUVANT BIOTECHNOLOGY PTY LIMITED (AU) | 2022-03-03 | — | — | US | claimed |
| WO-2009023357-A2 | CURCUMIN DERIVATIVES AND THEIR USE AS RADIOPROTECTORS | UNIVERSITY OF ROCHESTER (US) | 2009-02-19 | — | — | WO | claimed |
| EP-4727537-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | Adaxion Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4694924-A2 | METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING VACCINES | Rock Biomedical Inc. (TW) | 2026-02-18 | — | — | EP | disclosed |
| US-20260000609-A1 | METHODS AND COMPOSITIONS FOR TARGETED DELIVERY BY POLYMERSOMES | ROCK BIOMEDICAL INC (TW) | 2026-01-01 | — | — | US | disclosed |
| US-12508235-B2 | Methods and compositions for dendritic cell targeting nano-delivery | ROCK BIOMEDICAL, INC. (TW) | 2025-12-30 | — | — | US | disclosed |
| EP-4661844-A2 | METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING NANO-DELIVERY | Rock Biomedical Inc. (TW) | 2025-12-17 | — | — | EP | disclosed |
| US-20250195639-A1 | MULTI-EPITOPE MRNA SARS-COV-2 VACCINE FOR BOOSTING IMMUNITY THROUGH THE ACTIVATION OF CD4 AND CD8 T CELLS AS WELL AS B LYMPHOCYTES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-06-19 | — | — | US | disclosed |
| EP-4568709-A2 | METHODS AND COMPOSITIONS FOR TARGETED DELIVERY BY POLYMERSOMES | Rock Biomedical Inc. (TW) | 2025-06-18 | — | — | EP | disclosed |
| US-7928248-B2 | Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2276767-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009123971-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090247567-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009017874-A9 | NOVEL CURCUMIN DERIVATIVES AND THEIR PHARMACEUTICAL USES THEREOF | UNIV ROCHESTER (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009023357-A2 | CURCUMIN DERIVATIVES AND THEIR USE AS RADIOPROTECTORS | UNIVERSITY OF ROCHESTER (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009017874-A2 | NOVEL CURCUMIN DERIVATIVES AND THEIR PHARMACEUTICAL USES THEREOF | UNIVERSITY OF ROCHESTER (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12318485-B2 | Methods and compositions for targeted delivery by polymersomes | ALG1, CHMP4B, ALG8 | ALDH1A1 3184/4885HPGD 2903/4885KDM4E 4861/4885 |
| US-20260000609-A1 | METHODS AND COMPOSITIONS FOR TARGETED DELIVERY BY POLYMERSOMES | CD2, CLEC4M, CD47 | ALDH1A1 2855/4885HPGD 2899/4885KDM4E 3648/4885 |
| US-11603364-B2 | Acyl hydrazone derivative compounds for treating disease | FH, ACOX1, HDAC1 | ALDH1A1 451/4885HPGD 219/4885KDM4E 2092/4885 |
| US-12508235-B2 | Methods and compositions for dendritic cell targeting nano-delivery | CD4, CD47, LY6K | ALDH1A1 3306/4885HPGD 3670/4885KDM4E 2336/4885 |
| US-20220064142-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | SLC30A6, SLC39A11, SLC40A1 | ALDH1A1 507/4885HPGD 303/4885KDM4E 3502/4885 |
| US-20090247567-A1 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, BMX, PIK3CD | ALDH1A1 4004/4885HPGD 669/4885KDM4E 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.